ADH has a very high risk for breast cancer when coupled with BIRADS IV/V and superior breast tissue quantity. ADH on Main biopsy might represent inadequately sampled DCIS. carriers could be far better candidates for therapy with single-agent PARP inhibitors than triple-negative breast most ca